Toll-Like Receptors: New Therapeutic Targets for the Treatment of Atherosclerosis, Acute Coronary Syndromes, and Myocardial Failure
The toll-like receptors (TLRs) are a class of transmembrane molecules that have important functions in both innate and acquired immunity. As part of the bodyʼs normal immune defense against microbial pathogens, stimulation of these receptors will trigger the inflammatory response cascade and the rel...
Gespeichert in:
| Veröffentlicht in: | Cardiology in review 2008-11, Vol.16 (6), p.273-279 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 279 |
|---|---|
| container_issue | 6 |
| container_start_page | 273 |
| container_title | Cardiology in review |
| container_volume | 16 |
| creator | Erickson, Benjamin Sperber, Kirk Frishman, William H |
| description | The toll-like receptors (TLRs) are a class of transmembrane molecules that have important functions in both innate and acquired immunity. As part of the bodyʼs normal immune defense against microbial pathogens, stimulation of these receptors will trigger the inflammatory response cascade and the release of cytokines. Activation of these receptors also plays a role in a variety of systemic inflammatory diseases such as asthma, sepsis, atherosclerosis, acute coronary artery disease, and left ventricular remodeling. Pharmacologic approaches to modify the actions of TLRs are now under consideration as potential treatments for inflammatory systemic diseases that include atherosclerosis. At the same time, it is essential to characterize the benefits and risks of modifying such an important part of the bodyʼs innate immune system. |
| doi_str_mv | 10.1097/CRD.0b013e3181709fd8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69670928</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69670928</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2991-36dabf7e8e5576bc7b2720368ca7431bb6d4e633f4c1ebb06c2560f3cb099f233</originalsourceid><addsrcrecordid>eNpdkE1v1DAQhiNERT_gHyDkEydSxnbiONxWCy1I21Yq4WzZzoQNdeKt7Wi1Z_44rrpSJQ4z4_l6rXmK4j2FSwpt83l9__USDFCOnEraQDv08lVxRmsuy0pI_jq_QdCy5k1zWpzH-AeAUcrqN8UplS3jjMNZ8bfzzpWb8QHJPVrcJR_iF3KLe9JtMegdLmm0pNPhN6ZIBh9I2iLpAuo04ZyIH8gqV4KP1j35MX4iK7skJGsf_KzDgfw8zH3wE-aOnntyc_BWh37Ujlzp0S0B3xYng3YR3x3jRfHr6lu3_l5u7q5_rFeb0rK2pSUXvTZDgxLruhHGNoY1DLiQVjcVp8aIvkLB-VBZisaAsKwWMHBroG0HxvlF8fFZdxf844IxqWmMFp3TM_olKtGKjJHJPFg9D9p8UQw4qF0Yp3yLoqCe4KsMX_0PP699OOovZsL-ZelI-0V3713CEB_cssegtqhd2ioAqOqK1iUDkJTmtMyW__gHYyGSPQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69670928</pqid></control><display><type>article</type><title>Toll-Like Receptors: New Therapeutic Targets for the Treatment of Atherosclerosis, Acute Coronary Syndromes, and Myocardial Failure</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Erickson, Benjamin ; Sperber, Kirk ; Frishman, William H</creator><creatorcontrib>Erickson, Benjamin ; Sperber, Kirk ; Frishman, William H</creatorcontrib><description>The toll-like receptors (TLRs) are a class of transmembrane molecules that have important functions in both innate and acquired immunity. As part of the bodyʼs normal immune defense against microbial pathogens, stimulation of these receptors will trigger the inflammatory response cascade and the release of cytokines. Activation of these receptors also plays a role in a variety of systemic inflammatory diseases such as asthma, sepsis, atherosclerosis, acute coronary artery disease, and left ventricular remodeling. Pharmacologic approaches to modify the actions of TLRs are now under consideration as potential treatments for inflammatory systemic diseases that include atherosclerosis. At the same time, it is essential to characterize the benefits and risks of modifying such an important part of the bodyʼs innate immune system.</description><identifier>ISSN: 1061-5377</identifier><identifier>EISSN: 1538-4683</identifier><identifier>DOI: 10.1097/CRD.0b013e3181709fd8</identifier><identifier>PMID: 18923230</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins, Inc</publisher><subject>Acute Coronary Syndrome - drug therapy ; Acute Coronary Syndrome - immunology ; Acute Coronary Syndrome - physiopathology ; Anti-Inflammatory Agents - pharmacology ; Anti-Inflammatory Agents - therapeutic use ; Coronary Artery Disease - drug therapy ; Coronary Artery Disease - immunology ; Coronary Artery Disease - physiopathology ; Heart Failure - drug therapy ; Heart Failure - immunology ; Heart Failure - physiopathology ; Humans ; Immune System - drug effects ; Immune System - physiology ; Immunologic Factors - pharmacology ; Immunologic Factors - therapeutic use ; Toll-Like Receptors - drug effects ; Toll-Like Receptors - physiology</subject><ispartof>Cardiology in review, 2008-11, Vol.16 (6), p.273-279</ispartof><rights>2008 Lippincott Williams & Wilkins, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2991-36dabf7e8e5576bc7b2720368ca7431bb6d4e633f4c1ebb06c2560f3cb099f233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18923230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Erickson, Benjamin</creatorcontrib><creatorcontrib>Sperber, Kirk</creatorcontrib><creatorcontrib>Frishman, William H</creatorcontrib><title>Toll-Like Receptors: New Therapeutic Targets for the Treatment of Atherosclerosis, Acute Coronary Syndromes, and Myocardial Failure</title><title>Cardiology in review</title><addtitle>Cardiol Rev</addtitle><description>The toll-like receptors (TLRs) are a class of transmembrane molecules that have important functions in both innate and acquired immunity. As part of the bodyʼs normal immune defense against microbial pathogens, stimulation of these receptors will trigger the inflammatory response cascade and the release of cytokines. Activation of these receptors also plays a role in a variety of systemic inflammatory diseases such as asthma, sepsis, atherosclerosis, acute coronary artery disease, and left ventricular remodeling. Pharmacologic approaches to modify the actions of TLRs are now under consideration as potential treatments for inflammatory systemic diseases that include atherosclerosis. At the same time, it is essential to characterize the benefits and risks of modifying such an important part of the bodyʼs innate immune system.</description><subject>Acute Coronary Syndrome - drug therapy</subject><subject>Acute Coronary Syndrome - immunology</subject><subject>Acute Coronary Syndrome - physiopathology</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Coronary Artery Disease - drug therapy</subject><subject>Coronary Artery Disease - immunology</subject><subject>Coronary Artery Disease - physiopathology</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - immunology</subject><subject>Heart Failure - physiopathology</subject><subject>Humans</subject><subject>Immune System - drug effects</subject><subject>Immune System - physiology</subject><subject>Immunologic Factors - pharmacology</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Toll-Like Receptors - drug effects</subject><subject>Toll-Like Receptors - physiology</subject><issn>1061-5377</issn><issn>1538-4683</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1v1DAQhiNERT_gHyDkEydSxnbiONxWCy1I21Yq4WzZzoQNdeKt7Wi1Z_44rrpSJQ4z4_l6rXmK4j2FSwpt83l9__USDFCOnEraQDv08lVxRmsuy0pI_jq_QdCy5k1zWpzH-AeAUcrqN8UplS3jjMNZ8bfzzpWb8QHJPVrcJR_iF3KLe9JtMegdLmm0pNPhN6ZIBh9I2iLpAuo04ZyIH8gqV4KP1j35MX4iK7skJGsf_KzDgfw8zH3wE-aOnntyc_BWh37Ujlzp0S0B3xYng3YR3x3jRfHr6lu3_l5u7q5_rFeb0rK2pSUXvTZDgxLruhHGNoY1DLiQVjcVp8aIvkLB-VBZisaAsKwWMHBroG0HxvlF8fFZdxf844IxqWmMFp3TM_olKtGKjJHJPFg9D9p8UQw4qF0Yp3yLoqCe4KsMX_0PP699OOovZsL-ZelI-0V3713CEB_cssegtqhd2ioAqOqK1iUDkJTmtMyW__gHYyGSPQ</recordid><startdate>200811</startdate><enddate>200811</enddate><creator>Erickson, Benjamin</creator><creator>Sperber, Kirk</creator><creator>Frishman, William H</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200811</creationdate><title>Toll-Like Receptors: New Therapeutic Targets for the Treatment of Atherosclerosis, Acute Coronary Syndromes, and Myocardial Failure</title><author>Erickson, Benjamin ; Sperber, Kirk ; Frishman, William H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2991-36dabf7e8e5576bc7b2720368ca7431bb6d4e633f4c1ebb06c2560f3cb099f233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acute Coronary Syndrome - drug therapy</topic><topic>Acute Coronary Syndrome - immunology</topic><topic>Acute Coronary Syndrome - physiopathology</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Coronary Artery Disease - drug therapy</topic><topic>Coronary Artery Disease - immunology</topic><topic>Coronary Artery Disease - physiopathology</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - immunology</topic><topic>Heart Failure - physiopathology</topic><topic>Humans</topic><topic>Immune System - drug effects</topic><topic>Immune System - physiology</topic><topic>Immunologic Factors - pharmacology</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Toll-Like Receptors - drug effects</topic><topic>Toll-Like Receptors - physiology</topic><toplevel>online_resources</toplevel><creatorcontrib>Erickson, Benjamin</creatorcontrib><creatorcontrib>Sperber, Kirk</creatorcontrib><creatorcontrib>Frishman, William H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiology in review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erickson, Benjamin</au><au>Sperber, Kirk</au><au>Frishman, William H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Toll-Like Receptors: New Therapeutic Targets for the Treatment of Atherosclerosis, Acute Coronary Syndromes, and Myocardial Failure</atitle><jtitle>Cardiology in review</jtitle><addtitle>Cardiol Rev</addtitle><date>2008-11</date><risdate>2008</risdate><volume>16</volume><issue>6</issue><spage>273</spage><epage>279</epage><pages>273-279</pages><issn>1061-5377</issn><eissn>1538-4683</eissn><abstract>The toll-like receptors (TLRs) are a class of transmembrane molecules that have important functions in both innate and acquired immunity. As part of the bodyʼs normal immune defense against microbial pathogens, stimulation of these receptors will trigger the inflammatory response cascade and the release of cytokines. Activation of these receptors also plays a role in a variety of systemic inflammatory diseases such as asthma, sepsis, atherosclerosis, acute coronary artery disease, and left ventricular remodeling. Pharmacologic approaches to modify the actions of TLRs are now under consideration as potential treatments for inflammatory systemic diseases that include atherosclerosis. At the same time, it is essential to characterize the benefits and risks of modifying such an important part of the bodyʼs innate immune system.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>18923230</pmid><doi>10.1097/CRD.0b013e3181709fd8</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1061-5377 |
| ispartof | Cardiology in review, 2008-11, Vol.16 (6), p.273-279 |
| issn | 1061-5377 1538-4683 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69670928 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Acute Coronary Syndrome - drug therapy Acute Coronary Syndrome - immunology Acute Coronary Syndrome - physiopathology Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Coronary Artery Disease - drug therapy Coronary Artery Disease - immunology Coronary Artery Disease - physiopathology Heart Failure - drug therapy Heart Failure - immunology Heart Failure - physiopathology Humans Immune System - drug effects Immune System - physiology Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Toll-Like Receptors - drug effects Toll-Like Receptors - physiology |
| title | Toll-Like Receptors: New Therapeutic Targets for the Treatment of Atherosclerosis, Acute Coronary Syndromes, and Myocardial Failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A13%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Toll-Like%20Receptors:%20New%20Therapeutic%20Targets%20for%20the%20Treatment%20of%20Atherosclerosis,%20Acute%20Coronary%20Syndromes,%20and%20Myocardial%20Failure&rft.jtitle=Cardiology%20in%20review&rft.au=Erickson,%20Benjamin&rft.date=2008-11&rft.volume=16&rft.issue=6&rft.spage=273&rft.epage=279&rft.pages=273-279&rft.issn=1061-5377&rft.eissn=1538-4683&rft_id=info:doi/10.1097/CRD.0b013e3181709fd8&rft_dat=%3Cproquest_cross%3E69670928%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69670928&rft_id=info:pmid/18923230&rfr_iscdi=true |